贝伐单抗联合去甲基斑蝥素治疗卵巢癌患者的效果及对患者PAI-1表达的影响  

Effects of bevacizumab and norcantharidin for patients with oval cancer and on expression of PAI-1

作　　者：陆林 杨丽敏 徐成娟[1] Lu Lin;Yang Limin;Xu Chengjuan(Department of Gynecology,Shouguang People's Hospital,Shouguang 262700,China)

机构地区：[1]寿光市人民医院妇科,262700

出　　处：《国际医药卫生导报》2020年第22期3459-3461,共3页International Medicine and Health Guidance News

摘　　要：目的探讨贝伐单抗联合去甲基斑蝥素治疗卵巢癌患者的效果及对患者纤溶酶原激活物抑制因子-1(PAI-1)表达的影响。方法选取2016年1月至2018年4月本院收治的卵巢癌患者174例作为研究对象,将其随机分为研究组和对照组,各87例。对照组去甲基斑蝥素治疗,研究组则在此基础上应用贝伐单抗治疗,分析对比两组治疗效果、不良反应、生活质量以及PAI-1表达。结果研究组治疗效果显著优于对照组(P<0.05)。研究组不良反应总发生率显著低于对照组(P<0.05)。治疗前,两组生活质量评分差异无统计学意义(均P>0.05);治疗后,研究组认知水平、活动能力、社交能力、精神状态等评分显著优于对照组(均P<0.05);治疗前,两组PAI-1表达水平差异无统计学意义(P>0.05);治疗后1、3、5个月后,研究组PAI-1表达水平显著低于对照组(均P<0.05)。结论贝伐单抗联合去甲基斑蝥素治疗卵巢癌患者临床效果显著,可有效降低患者不良反应发生率,改善患者生活质量以及稳定PAI-1表达水平,可作为卵巢癌治疗的首选方案。Objective To investigate the effects of bevacizumab and norcantharidin for patients with oval cancer and on expression of plasminogen activator inhibitor-1(PAI-1).Methods 174 patients with oval cancer treated at our hospital from January,2016 to April,2018 were selected as study objects,and were randomly divided into a study group and a control group,with 87 cases in each group.The control group were treated with norcantharidin,and the study group with bevacizumab and norcantharidin.The treatment effects,adverse reactions,life quality,and expression of PAI-1 were compared between these two groups.Results The treatment effect was better and the incidence of adverse reactions was lower in the study group than in the control group(both P<0.05).Before the treatment,there were no statistical differences in the scores of life quality between the two groups(all P>0.05);after the treatment,and the scores of cognitive level,activity ability,social ability,and mental state were significantly better in study group than in the control group(all P<0.05).Before the treatment,there was no statistical difference in the level of PAI-1 between the two groups(P>0.05);1,3,and 5 months after the treatment,the levels of PAI-1 were significantly lower in the study group than in the control group(all P<0.05).Conclusion Bevacizumab and norcantharidin for patients with oval cancer is clinically effectively,and can decrease the incidence of adverse reactions and improve their life quality and PAI-1 level,so it is a first choice for oval cancer.

关 键 词：贝伐单抗 去甲基斑蝥素 卵巢癌 PAI-1 

分 类 号：R737.31[医药卫生—肿瘤]